Biogen beats Q4 top and bottom line estimates; initiates FY23 outlook
Biogen press release  (NASDAQ:BIIB): Q4  Non-GAAP EPS of $4.05  beats by $0.57.
Revenue of $2.54B (-7.3% Y/Y)  beats by $100M.
As of December 31, 2022, Biogen had cash, cash equivalents, and marketable securities totaling $5,598 million and $6,281 million in total debt, resulting in net debt of $683 million.

Full Year 2023 Financial Guidance: Expect mid-single digit revenue decline versus 2022 and Non-GAAP EPS of $15.00 to $16.00 vs. consensus of $15.76.